Caladrius Biosciences Stock Forecast, Price & News

-0.02 (-1.48 %)
(As of 07/30/2021 05:17 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume198,174 shs
Average Volume3.15 million shs
Market Capitalization$79.13 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CLBS News and Ratings via Email

Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Caladrius Biosciences logo

About Caladrius Biosciences

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.53 out of 5 stars

Medical Sector

925th out of 2,216 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

16th out of 30 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions

Is Caladrius Biosciences a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Caladrius Biosciences stock.
View analyst ratings for Caladrius Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Caladrius Biosciences?

Wall Street analysts have given Caladrius Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Caladrius Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Caladrius Biosciences' next earnings date?

Caladrius Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Caladrius Biosciences

How can I listen to Caladrius Biosciences' earnings call?

Caladrius Biosciences will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "42180".

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences, Inc. (NASDAQ:CLBS) posted its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.10.
View Caladrius Biosciences' earnings history

How has Caladrius Biosciences' stock been impacted by Coronavirus?

Caladrius Biosciences' stock was trading at $2.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLBS shares have decreased by 40.6% and is now trading at $1.33.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CLBS?

2 brokerages have issued 12 month target prices for Caladrius Biosciences' shares. Their forecasts range from $10.00 to $14.00. On average, they anticipate Caladrius Biosciences' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 802.3% from the stock's current price.
View analysts' price targets for Caladrius Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the following people:
  • Dr. David J. Mazzo, Pres, CEO & Director (Age 64, Pay $972.93k)
  • Mr. Todd C. Girolamo M.B.A., J.D., Esq., Chief Legal Officer, Sr. VP of Corp. Devel. & Corp. Sec. (Age 55, Pay $456.39k)
  • Dr. William K. Sietsema Ph.D., VP of Global Regulatory Affairs (Age 65, Pay $350.55k)
  • Mr. James Nisco, VP of Fin. & Treasury
  • Mr. Gregory S. Berkin, VP of Information Technology & Cyber security and Chief Information Officer
  • Mr. John D. Menditto, VP of Investor Relations & Corp. Communications
  • Eric Powers, Director of Communications and Marketing
  • Ms. Gail Holler, VP of HR (Age 62)
  • Dr. Robert M. Honigberg, Interim Chief Medical Officer (Age 60)
  • Dr. Ian Zhang Ph.D., MBA, Pres of NeoStem (China), Inc and Managing Director of NeoStem (China), Inc (Age 56)

What is David J. Mazzo's approval rating as Caladrius Biosciences' CEO?

1 employees have rated Caladrius Biosciences CEO David J. Mazzo on David J. Mazzo has an approval rating of 100% among Caladrius Biosciences' employees. This puts David J. Mazzo in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Caladrius Biosciences' key competitors?

What other stocks do shareholders of Caladrius Biosciences own?

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How do I buy shares of Caladrius Biosciences?

Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Caladrius Biosciences' stock price today?

One share of CLBS stock can currently be purchased for approximately $1.33.

How much money does Caladrius Biosciences make?

Caladrius Biosciences has a market capitalization of $79.13 million. The biotechnology company earns $-8,150,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis.

How many employees does Caladrius Biosciences have?

Caladrius Biosciences employs 24 workers across the globe.

When was Caladrius Biosciences founded?

Caladrius Biosciences was founded in 2006.

What is Caladrius Biosciences' official website?

The official website for Caladrius Biosciences is

Where are Caladrius Biosciences' headquarters?

Caladrius Biosciences is headquartered at 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.